Scottish Medicines Consortium accepts Theramex’ Bijuve HRT on NHS Scotland

13 September 2022 - The first and only body identical HRT for post-menopausal oestrogen deficiency, Bijuve, has been passed by ...

Read more →

The SMC recommends use of Hansa Biopharma's Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients

12 September 2022 - The SMC decision follows the recent positive NICE recommendation for Idefirix in England, Wales and Northern ...

Read more →

Chiesi’s Trimbow recommended for use within NHS Scotland

18 August 2022 - The SMC approval brings much needed boost to asthma sufferers across Scotland. ...

Read more →

SMC approve Johnson & Johnson’s systemic light chain amyloidosis therapy

10 August 2022 - Newly diagnosed patients will become the first to access systemic light chain amyloidosis treatment in the ...

Read more →

SMC - August 2022 decisions

8 August 2022 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...

Read more →

SMC - July 2022 decisions

11 July 2022 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...

Read more →

SMC - June 2022 decisions

13 June 2022 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...

Read more →

First treatment option indicated for CKD in Scotland for 20 years

10 May 2022 - NICE recommendation for Forxiga could entitle 53,000 adults to the new kidney disease therapy ...

Read more →

SMC - May 2022 decisions

9 May 2022 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...

Read more →

SMC - April 2022 decisions

12 April 2022 - Advice on three new medicines for use in conditions including a rare and fatal genetic condition affecting ...

Read more →

New access tool launched as part of SMC’s joint work on streamlining patient access to innovative medicines

8 March 2022 - A new UK wide health technology assessment access forum has been developed by partners including the ...

Read more →

SMC accepts Lumykras (sotorasib) for locally advanced or metastatic non-small cell lung cancer for use on an interim basis by NHS Scotland

7 March 2022 - Sotorasib Is indicated as monotherapy for the treatment of adult patients with KRAS G12C mutated locally advanced ...

Read more →

SMC approval welcome news for breast cancer patients

9 March 2022 - Trodelvy is accepted for use in metastatic triple negative breast cancer. patients who have already received two ...

Read more →

Scottish Medicines Consortium update

7 March 2022 - Diurnal provides an update on the status of reimbursement of Efmody (modified release hydrocortisone) for NHS ...

Read more →

SMC - March 2022 decisions

7 March 2022 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...

Read more →